| BLDR |
Report |
Net Revenue (Q2 2026) |
BEAT |
pred ~$3,970M vs. cons $3,920M |
MEDIUM |
| BLDR |
Report |
Adj. EBITDA (Q2 2026) |
MISS |
pred ~$322M vs. cons $331.6M |
MEDIUM |
| BLDR |
Report |
Gross Margin % (Q2 2026) |
IN-LINE |
pred ~28.1% vs. cons ~28.3% |
MEDIUM |
| BLDR |
Guide |
FY 2026 Adj. EBITDA (FY 2026) |
LOWER |
guide mid ~$1,225M vs. cons $1,202M |
MEDIUM |
| BLDR |
Guide |
FY 2026 Revenue (FY 2026) |
LOWER |
guide mid ~$15.0B vs. cons $14,768M |
MEDIUM |
| BLDR |
Guide |
Q3 2026 Revenue/EBITDA (Q3 2026) |
LOWER |
guide below current Q3 consensus |
MEDIUM |
| BLDR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
MEDIUM |
| BLDR |
Return |
5-day cumulative residual |
-2.5% (FADE) |
FADE — initial relief on revenue beat, then sell-side cuts Q3/FY estimates on guide narrowed lower; archetype D 5-day pattern |
MEDIUM |